Literature DB >> 12237628

Antimicrobial components of vaginal fluid.

Erika V Valore1, Christina H Park, Sorina L Igreti, Tomas Ganz.   

Abstract

OBJECTIVE: We examined the antimicrobial activity and composition of vaginal fluid. STUDY
DESIGN: Vaginal fluid from preweighed tampons was assayed for pH, lactic acid, and antimicrobial polypeptides. The fluid was also fractionated by molecular filtration. Antimicrobial activity of whole fluid was determined against representative resident and exogenous microbes, and its fractions were tested against Escherichia coli.
RESULTS: Vaginal fluids (5/5 donors) were permissive for Lactobacillus crispatus and vaginalis and Candida albicans, but not for Escherichia coli, Streptococcus group B, and Lactobacillus jensenii in three of five donors. The antimicrobial activity against E coli was predominantly in a <3-kd fraction and correlated with both low pH and high lactic acid content. Compared with a matched pH buffer, lactic acid markedly suppressed the growth of E coli. Concentrated 2- or 5-fold, the protein-rich fraction was active against E coli.
CONCLUSION: Vaginal fluid exerts selective antimicrobial activity against nonresident bacterial species. The activity is mediated by lactic acid, low pH, and antimicrobial polypeptides.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237628     DOI: 10.1067/mob.2002.125280

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  86 in total

1.  NATURAL ANTIMICROBIALS AND THEIR ROLE IN VAGINAL HEALTH: A SHORT REVIEW.

Authors:  S E Dover; A A Aroutcheva; S Faro; M L Chikindas
Journal:  Int J Probiotics Prebiotics       Date:  2008

2.  The impact of pregnancy on anti-HIV activity of cervicovaginal secretions.

Authors:  Brenna L Hughes; Riana Dutt; Christina Raker; Melody Barthelemy; Richard M Rossoll; Bharat Ramratnam; Charles R Wira; Susan Cu-Uvin
Journal:  Am J Obstet Gynecol       Date:  2016-07-05       Impact factor: 8.661

3.  A High-throughput Bead-based Affinity Assay Enables Analysis of Genital Protein Signatures in Women At Risk of HIV Infection.

Authors:  Anna Månberg; Frideborg Bradley; Ulrika Qundos; Brandon L Guthrie; Kenzie Birse; Laura Noël-Romas; Cecilia Lindskog; Rose Bosire; James Kiarie; Carey Farquhar; Adam D Burgener; Peter Nilsson; Kristina Broliden
Journal:  Mol Cell Proteomics       Date:  2018-11-30       Impact factor: 5.911

4.  Human alpha-defensins block papillomavirus infection.

Authors:  Christopher B Buck; Patricia M Day; Cynthia D Thompson; Jacek Lubkowski; Wuyuan Lu; Douglas R Lowy; John T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

5.  The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct.

Authors:  Amy L Cole; Anna Herasimtschuk; Phalguni Gupta; Alan J Waring; Robert I Lehrer; Alexander M Cole
Journal:  Immunology       Date:  2007-01-23       Impact factor: 7.397

Review 6.  Vaginal drug delivery systems for HIV prevention.

Authors:  Lisa Cencia Rohan; Alexandra B Sassi
Journal:  AAPS J       Date:  2009-02-05       Impact factor: 4.009

Review 7.  Innate and adaptive anti-HIV immune responses in the female reproductive tract.

Authors:  Marta Rodriguez-Garcia; Mickey V Patel; Charles R Wira
Journal:  J Reprod Immunol       Date:  2013-03       Impact factor: 4.054

8.  An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.

Authors:  Marc M Baum; Irina Butkyavichene; Scott A Churchman; Gilbert Lopez; Christine S Miller; Thomas J Smith; John A Moss
Journal:  Int J Pharm       Date:  2015-09-16       Impact factor: 5.875

9.  Innate immunity in the vagina (Part II): Anti-HIV activity and antiviral content of human vaginal secretions.

Authors:  Mickey V Patel; Mimi Ghosh; John V Fahey; Christina Ochsenbauer; Richard M Rossoll; Charles R Wira
Journal:  Am J Reprod Immunol       Date:  2014-05-08       Impact factor: 3.886

10.  Theaflavin-3,3'-digallate and lactic acid combinations reduce herpes simplex virus infectivity.

Authors:  Charles E Isaacs; Weimin Xu
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.